NASDAQ · SION
Sionna Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SION: Nov 4, 2026
Sionna Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.62. The reported EPS for the same quarter last year was $-0.46.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.62 | $-0.53 | $-0.69 | 3 |
| Dec 2026 | $-0.63 | $-0.48 | $-0.80 | 3 |
| Mar 2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Jun 2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews · BNK Invest- Zacks · Oct 12, 8:35 AM EDTSionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in th
- The Motley Fool · Sep 18, 1:20 PM EDTIs This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?Vertex Pharmaceuticals has declined meaningfully from its most recent high.
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- Zacks · Sep 16, 11:26 AM EDTSION to Cut Workforce by Nearly Half After CF Study Failure, Stock DownSionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
- RTTNews · Sep 15, 10:08 AM EDTSionna Advances New CF Combo To Phase 2a After SION-719 Setback, Cuts Workforce 46%; Stock Down(RTTNews) – Sionna Therapeutics Inc. (SION), a clinical-stage biopharmaceutical company developing treatments for cystic fibrosis (CF), announced plans to advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial.
- The Motley Fool · Sep 4, 2:50 PM EDTVertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area.
- BNK Invest · Aug 25, 7:11 AM EDTSionna Therapeutics Reaches Analyst Target PriceIn recent trading, shares of Sionna Therapeutics Inc (Symbol: SION) have crossed above the average analyst 12-month target price of $5.50, changing hands for $5.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o
- The Motley Fool · Aug 20, 3:50 PM EDTVertex Pharmaceuticals' Rally Has a New Engine — and Wall Street Thinks the Best Is Still AheadVertex Pharmaceuticals' business could be in trouble if it faces competition in its core market.
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- The Motley Fool · Aug 14, 4:20 PM EDTVertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even MoreVertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area.
- MarketBeat · Aug 11, 12:03 AM EDTSionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination PathSionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis. The co
- NASDAQ.com · Aug 10, 8:29 AM EDTPre-Market Most Active for Aug 10, 2026 : SPCX, ACHR, ABCL, SION, INTC, IPHA, SLN, CHMI, NOK, HZO, B, IONQThe NASDAQ 100 Pre-Market Indicator is down -31.07 to 29,691.23. The total Pre-Market volume is currently 110,469,046 shares traded.The following are the most active stocks for the pre-market session: Space Exploration Technologies Corp. (SPCX) is +2.99 at $136.10, with 9,630,42
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Sionna Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.